Hyperion Therapeutics Inc. (NASDAQ:HPTX)

Hyperion Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. It is developing Ravicti, which has completed two Phase II trials and one Phase III trial for the treatment of adult and pediatric urea cycle disorders patients; and is in Phase II clinical trial for the treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in South San Francisco, California.

Last updated March 14, 2013